<p>Merus N.V.（纳斯达克代码：MRUS - 获取免费报告）在周五收到了异常活跃的期权交易活动。股票投资者购买了 52,417 份该公司的看涨期权。这比典型的 1,434 份看涨期权的交易量增加了 3,555%。</p>
<h2>Merus 股票上涨 0.0%</h2>
<p>在周五的交易时段，纳斯达克：MRUS 上涨了 0.01 美元，达到了 96.92 美元。该公司的交易量为 362,694 股，而其平均交易量为 1,259,284 股。该股票的 50 日移动平均为 95.83 美元，200 日移动平均为 76.91 美元。Merus 的年内最低价为 33.19 美元，年内最高价为 97.14 美元。该公司的市值为 73.5 亿美元，市盈率为-18.29，贝塔值为 1.06。</p>
<h2>Merus 的内部买卖</h2>
<p>在相关消息中，主要股东 A/S Genmab 于 12 月 18 日星期四收购了 212,177 股该公司的股票。每股的平均收购成本为 97.00 美元，总价值为 20,581,169.00 美元。收购后，内部人士持有 71,946,801 股该公司的股票，估值约为 6,978,839,697 美元。此次交易使其持股比例增加了 0.30%。该收购已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，副总裁 Harry Shuman 于 11 月 25 日星期二出售了 8,300 股该公司的股票。该股票以平均价格 95.92 美元出售，总价值为 796,136.00 美元。出售完成后，副总裁持有 11,002 股该公司的股票，估值约为 1,055,311.84 美元。此次交易使其持股比例减少了 43.00%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共购入了价值 53,348,836 美元的 549,988 股公司股票。公司内部人士持有公司 3.70% 的股份。</p>
<h2>Merus 的机构交易</h2>
<p>大型投资者最近增加或减少了在该公司的持股。CWM LLC 在第二季度将其在 Merus 的股份增加了 299.0%。CWM LLC 现在拥有 802 股该生物技术公司的股票，估值为 42,000 美元，此前在上个季度又收购了 601 股。Quarry LP 在第三季度以 42,000 美元的估值购买了 Merus 的新头寸。Farther Finance Advisors LLC 在第三季度将其在 Merus 的股份增加了 10,400.0%。Farther Finance Advisors LLC 现在拥有 525 股该生物技术公司的股票，价值 49,000 美元，此前在上个季度又购买了 520 股。Longfellow Investment Management Co. LLC 在第三季度购买了价值 75,000 美元的 Merus 新股份。最后，Quantbot Technologies LP 在第三季度以约 114,000 美元的估值购买了 Merus 的新头寸。96.14% 的股票由机构投资者持有。</p>
<h2>分析师设定新的目标价</h2>
<p>几家券商最近对 MRUS 发表了评论。Canaccord Genuity Group 将 Merus 的股票评级从 “买入” 下调至 “持有”，并将其目标价从 67.00 美元上调至 97.00 美元，报告日期为 9 月 29 日星期一。Lifesci Capital 重申了 “市场表现” 评级，并在 9 月 30 日星期二的研究报告中设定了 97.00 美元的目标价。巴克莱在 9 月 30 日星期二的研究报告中重申了 “同等权重” 评级，并将 Merus 的目标价设定为 97.00 美元（之前为 112.00 美元）。William Blair 在 9 月 29 日星期一将 Merus 的评级从 “强力买入” 下调至 “持有”。最后，BMO 资本市场在 10 月 31 日星期五的研究报告中重申了 “市场表现” 评级，并设定了 97.00 美元的目标价。三位股票研究分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，平均目标价为 93.56 美元。</p>
<p><strong>阅读我们对 Merus 的最新分析</strong></p>
<h2>关于 Merus</h2>
<p>（获取免费报告）</p>
<p>Merus NV 是一家临床阶段的免疫肿瘤学公司，专注于双特异性抗体治疗药物的发现和开发，以治疗癌症。利用其专有的 Biclonics®平台，Merus 设计了完全人源的双特异性抗体，旨在同时与免疫细胞和肿瘤靶点结合。该公司的研究工作旨在创造具有优化效力、选择性和安全性特征的新疗法。</p>
<p>Merus 的产品管线涵盖多个处于不同临床和前临床开发阶段的 Biclonics 候选药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>美国结束更新</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>[如何] 认领您在 SpaceX 的 IPO 前股份！</li>
<li>用这四个简单步骤保护您的银行账户</li>
<li>SRCRF 通往内华达州黄金财富的旅程。</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
<p>在考虑 Merus 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Merus 并不在名单上。</p>
<p>虽然 Merus 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRUS

<p>Merus N.V.（纳斯达克代码：MRUS）经历了显著的看涨期权交易增长，购入了 52,417 份期权，较平均交易量上涨了 3,555%。股价小幅上涨至 96.92 美元。内部交易活动中，主要股东 A/S Genmab 购入了股份，而副总裁 Harry Shuman 则出售了股份。机构投资者持有 96.14% 的股份。分析师的评级意见不一，平均目标价为 93.56 美元。Merus 专注于用于癌症治疗的双特异性抗体疗法</p>

<p>Merus N.V. (NASDAQ:MRUS - Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors purchased 52,417 call options on the company. This represents an increase of 3,555% compared to the typical volume of 1,434 call options.</p>
<div class="lb-trans"><p>Merus N.V.（纳斯达克代码：MRUS - 获取免费报告）在周五收到了异常活跃的期权交易活动。股票投资者购买了 52,417 份该公司的看涨期权。这比典型的 1,434 份看涨期权的交易量增加了 3,555%。</p>
</div><h2>Merus Stock Up 0.0%</h2>
<div class="lb-trans"><h2>Merus 股票上涨 0.0%</h2>
</div><p>NASDAQ:MRUS traded up $0.01 during trading hours on Friday, reaching $96.92. The company had a trading volume of 362,694 shares, compared to its average volume of 1,259,284. The stock has a 50-day moving average of $95.83 and a two-hundred day moving average of $76.91. Merus has a one year low of $33.19 and a one year high of $97.14. The firm has a market capitalization of $7.35 billion, a PE ratio of -18.29 and a beta of 1.06.</p>
<div class="lb-trans"><p>在周五的交易时段，纳斯达克：MRUS 上涨了 0.01 美元，达到了 96.92 美元。该公司的交易量为 362,694 股，而其平均交易量为 1,259,284 股。该股票的 50 日移动平均为 95.83 美元，200 日移动平均为 76.91 美元。Merus 的年内最低价为 33.19 美元，年内最高价为 97.14 美元。该公司的市值为 73.5 亿美元，市盈率为-18.29，贝塔值为 1.06。</p>
</div><h2>Insider Buying and Selling at Merus</h2>
<div class="lb-trans"><h2>Merus 的内部买卖</h2>
</div><p>In related news, major shareholder A/S Genmab acquired 212,177 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $97.00 per share, with a total value of $20,581,169.00. Following the purchase, the insider owned 71,946,801 shares of the company's stock, valued at approximately $6,978,839,697. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, VP Harry Shuman sold 8,300 shares of the business's stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $95.92, for a total value of $796,136.00. Following the completion of the sale, the vice president owned 11,002 shares of the company's stock, valued at approximately $1,055,311.84. This trade represents a 43.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have acquired 549,988 shares of company stock worth $53,348,836 over the last three months. Company insiders own 3.70% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，主要股东 A/S Genmab 于 12 月 18 日星期四收购了 212,177 股该公司的股票。每股的平均收购成本为 97.00 美元，总价值为 20,581,169.00 美元。收购后，内部人士持有 71,946,801 股该公司的股票，估值约为 6,978,839,697 美元。此次交易使其持股比例增加了 0.30%。该收购已在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，副总裁 Harry Shuman 于 11 月 25 日星期二出售了 8,300 股该公司的股票。该股票以平均价格 95.92 美元出售，总价值为 796,136.00 美元。出售完成后，副总裁持有 11,002 股该公司的股票，估值约为 1,055,311.84 美元。此次交易使其持股比例减少了 43.00%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共购入了价值 53,348,836 美元的 549,988 股公司股票。公司内部人士持有公司 3.70% 的股份。</p>
</div><h2>Institutional Trading of Merus</h2>
<div class="lb-trans"><h2>Merus 的机构交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Merus by 299.0% in the second quarter. CWM LLC now owns 802 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 601 shares during the last quarter. Quarry LP bought a new position in Merus in the 3rd quarter valued at $42,000. Farther Finance Advisors LLC boosted its stake in Merus by 10,400.0% in the third quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 520 shares in the last quarter. Longfellow Investment Management Co. LLC bought a new stake in shares of Merus during the third quarter worth $75,000. Finally, Quantbot Technologies LP bought a new position in shares of Merus in the third quarter valued at about $114,000. 96.14% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了在该公司的持股。CWM LLC 在第二季度将其在 Merus 的股份增加了 299.0%。CWM LLC 现在拥有 802 股该生物技术公司的股票，估值为 42,000 美元，此前在上个季度又收购了 601 股。Quarry LP 在第三季度以 42,000 美元的估值购买了 Merus 的新头寸。Farther Finance Advisors LLC 在第三季度将其在 Merus 的股份增加了 10,400.0%。Farther Finance Advisors LLC 现在拥有 525 股该生物技术公司的股票，价值 49,000 美元，此前在上个季度又购买了 520 股。Longfellow Investment Management Co. LLC 在第三季度购买了价值 75,000 美元的 Merus 新股份。最后，Quantbot Technologies LP 在第三季度以约 114,000 美元的估值购买了 Merus 的新头寸。96.14% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的目标价</h2>
</div><p>Several brokerages recently commented on MRUS. Canaccord Genuity Group downgraded shares of Merus from a &#34;buy&#34; rating to a &#34;hold&#34; rating and lifted their target price for the stock from $67.00 to $97.00 in a report on Monday, September 29th. Lifesci Capital reissued a &#34;market perform&#34; rating and set a $97.00 price objective on shares of Merus in a research report on Tuesday, September 30th. Barclays restated an &#34;equal weight&#34; rating and set a $97.00 target price (down previously from $112.00) on shares of Merus in a research note on Tuesday, September 30th. William Blair lowered Merus from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, September 29th. Finally, BMO Capital Markets reaffirmed a &#34;market perform&#34; rating and set a $97.00 target price on shares of Merus in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and an average price target of $93.56.</p>
<div class="lb-trans"><p>几家券商最近对 MRUS 发表了评论。Canaccord Genuity Group 将 Merus 的股票评级从 “买入” 下调至 “持有”，并将其目标价从 67.00 美元上调至 97.00 美元，报告日期为 9 月 29 日星期一。Lifesci Capital 重申了 “市场表现” 评级，并在 9 月 30 日星期二的研究报告中设定了 97.00 美元的目标价。巴克莱在 9 月 30 日星期二的研究报告中重申了 “同等权重” 评级，并将 Merus 的目标价设定为 97.00 美元（之前为 112.00 美元）。William Blair 在 9 月 29 日星期一将 Merus 的评级从 “强力买入” 下调至 “持有”。最后，BMO 资本市场在 10 月 31 日星期五的研究报告中重申了 “市场表现” 评级，并设定了 97.00 美元的目标价。三位股票研究分析师对该股票给予了买入评级，十四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “持有”，平均目标价为 93.56 美元。</p>
</div><p><strong>Read Our Latest Analysis on Merus</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Merus 的最新分析</strong></p>
</div><h2>About Merus</h2>
<div class="lb-trans"><h2>关于 Merus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company's research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.</p>
<div class="lb-trans"><p>Merus NV 是一家临床阶段的免疫肿瘤学公司，专注于双特异性抗体治疗药物的发现和开发，以治疗癌症。利用其专有的 Biclonics®平台，Merus 设计了完全人源的双特异性抗体，旨在同时与免疫细胞和肿瘤靶点结合。该公司的研究工作旨在创造具有优化效力、选择性和安全性特征的新疗法。</p>
</div><p>The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Merus 的产品管线涵盖多个处于不同临床和前临床开发阶段的 Biclonics 候选药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>End of America update</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>[How To] Claim Your Pre-IPO Stake In SpaceX!</li>
<li>Protect Your Bank Account with THESE 4 Simple Steps</li>
<li>SRCRF’s Journey to Nevada Gold Riches.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>美国结束更新</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>[如何] 认领您在 SpaceX 的 IPO 前股份！</li>
<li>用这四个简单步骤保护您的银行账户</li>
<li>SRCRF 通往内华达州黄金财富的旅程。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Merus 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Merus 并不在名单上。</p>
</div><p>While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merus 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

股票交易者大量买入 Merus（NASDAQ:MRUS）的看涨期权